{
  "docId": "019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "docSlug": "86e21d9d1e23",
  "documentTitle": "PMV Pharmaceuticals (PMVP)",
  "authorId": "60_Wolfpack_Research",
  "authorName": "Wolfpack Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-05-19 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 10,
  "pageCount": 19,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses preclinical data to cast doubt on the clinical viability of the drug candidate.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-8c03a48e7d6f/10",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f#slide-10",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "These data reinforce our concerns about the potency of the drug, with doses as high as 300 mg/kg needed just to maintain tumor size (i.e., stable disease).",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a678-4a0c052807c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.78,
        "x": 0.11,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Mouse tumor volume study charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6a103f4-8172-479a-8af7-576b2f0d7a11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "tumor volume: 300 mg/kg",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a678-4eb2b7b9f516",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.78,
        "x": 0.11,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "The half-life of PC14586 at 100 mg/kg is reported to be ~7.5 hours. This short half-life of the drug is a concern. PC14586 needs to be administered daily (QD) at doses greater than 570 mg. PC14586 knocks down mutant p53 ~8 hours after an oral dose, as expected, but the level bounces back to roughly half the pre-dose level at 24 hours.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0305696a-0cce-47f5-a580-4e9b2a77256a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Some additional mouse model data can be found in the patent. These data reinforce our concerns about the potency of the drug, with doses as high as 300 mg/kg needed just to maintain tumor size (i.e., stable disease).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fd386e6-ef89-40f1-a2e2-d14aea3a810f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "PMV Pharma is conducting a Phase 1 healthy volunteer study to investigate the food effects on dosing. It is curious that the company has progressed into a Phase 1/2 dose-escalation study before fully understanding the pharmacokinetics of the drug.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "849050bb-651a-477b-b782-eb9cc1ca38fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.11,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Patent, WO2021262483A1; PMVP, 10-K, 3/1/2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "208ba27e-750a-4ef9-b8e0-d33d598a4e34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.68
      },
      "kind": "title",
      "text": "PMV’s Lead Drug Candidate Has a Narrow Therapeutic Window, Indicating That the Drug May Not Restore Normal Cell Function Long Enough to Generate Durable Tumor Regression in Humans",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "415575ba-6e61-420d-b68f-e213369a1c38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.11,
        "y": 0.09
      },
      "kind": "title",
      "text": "Additional Data from Mice Indicate That PMV’s Leading Drug Candidate Lacks Potency",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05d1a09a-801f-4744-a896-ef3713012ce3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 3,
      "beatId": "f89a3578-3b10-48a0-a0dc-890f21967937",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": "overcoming-monster-the-monster",
      "evidence": "The document exposes contradictions and concerns regarding PMV Pharma's drug candidate.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}